Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.

ABSTRACT:

Importance

Metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) shows frequent and durable responses to programmed cell death 1 blockade. While most of these tumors are sporadic and observed in older patients, first-line pembrolizumab data are limited to findings from the KEYNOTE-177 trial (A Phase III Study of Pembrolizumab [MK-3475] vs Chemotherapy in Microsatellite Instability-High [MSI-H] or Mismatch Repair Deficient [dMMR] Stage IV Colorectal Carcinoma).

Objective

To investigate outcome with first-line pembrolizumab monotherapy in mostly older patients with dMMR mCRC at a multisite clinical practice.

Design, setting, and participants

This cohort study included consecutive patients with dMMR mCRC who received pembrolizumab monotherapy betw

SUBMITTER: Saberzadeh-Ardestani B 

PROVIDER: S-EPMC9947726 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature